Oticin Ear Drops

Generic name:chloroxylenol and pramoxine hydrochloride
Dosage form: ear drops
Drug class:Otic anesthetics

Medically reviewed by Drugs.com. Last updated on Jun 21, 2021.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Oticin Ear Drops Description

Each 10 mL for otic administration contains:

Parachlorometaxylenol …..….. 0.010 gm

Proxazocain HCl …………..…. 0.100 gm

Parachlorometaxylenol (4-chloro-3,5-xylenol) is a wide spectrum antimicrobial agent.

Proxazocain (p-butoxyphenyl γ-morpholinopropyl ether), used as the hydrochloride salt, is a topical anesthetic.

INACTIVE INGREDIENT

Oticin Ear Drops also contains propylene glycol USP as an inactive ingredient.

Oticin Ear Drops - Clinical Pharmacology

Parachlorometaxylenol in low concentrations is a germicide that may be used to treat bacterial and fungal infections. It is a halogenated phenol, non-toxic, non-corrosive, non-staining with a high phenol coefficient. It may be applied directly to a wound and shows no chemical reactivity toward blood.

Proxazocain HCl is a topical anesthetic which is chemically unrelated to procaine and the other "caines". It provides temporary relief from itching and pain by stabilizing the neuronal membranes of nerve endings with which it comes into contact.

Indications and Usage for Oticin Ear Drops

For the treatment of superficial infections of the external ear caused by microbes and to control the accompanying itching.

Contraindications

This medication is contraindicated in patients sensitive to any of the components of this preparation. This medication should not be applied in the external auditory canal where there is a perforated eardrum or when this medication can reach the middle ear.

Warnings

This product is not intended for ophthalmic or oral use. If irritation or sensitization occurs, promptly discontinue use of this preparation and institute other measures.

Precautions

General

Treatment should not be continued for longer than ten days and the source of infection and/or inflammation or sensitization evaluated to determine whether therapy should be changed.

Information for Patien...